Xilio Therapeutics, Inc.

NASDAQ:XLO

Biotechnology

Healthcare
$7.63 +5.14%

+$0.45 today

Market cap
$53.90M
Beta
-0.09
P/E (TTM)
-48.1
EPS (TTM)
-$0.19
52W Low $6.47High $12.74

Volume 0.01M

Average 0.05M

XLO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Xilio Therapeutics, Inc.NASDAQ: XLO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $19.83M rose 139.9% year over year, ahead of the +73.0% change in trailing-twelve-month research & development. Sequentially, it rose 9.4% from the prior quarter. Over 3 fiscal years it compounded at -1.8% a year.

Context

  • Research & development amounted to 128.0% of revenue in FY2025, down 521.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +139.9% holds above the trailing-twelve-month pace of +73.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.83M+9.4% QoQ
Last fiscal yearDec 2025
$56.04M+36.0% YoY
LTMMar 2026
$67.61M+73.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+139.9%——
1 year+36.0%——
3-year CAGR-1.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
56.04M USD
Year-over-year change
+36.0%
4-year CAGR
+2.3%

Research & Development vs competitors

How XLO compares with its peers on the latest reported figures

  • XLO's LTM Mar 2026 research & development of $67.61M is the highest of the 4 companies compared; the peer median is $18.74M.
  • Its year-over-year change of +73.0% is the highest of 4, against a peer median of -24.3%.
  • Research & development amounts to 126.4% of revenue for XLO, versus a peer median of 53.4%.
XLO Competitors Peer median
Research & Development for XLO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$67.61M +73.0%-1.8%126.4%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$46.96M -24.3%+23.1%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$18.74M -30.0%-3.0%53.4%
PDSBPDS Biotechnology CorporationLTM Mar 2026$16.65M -23.2%-13.5%—
Peer median (excluding XLO) $18.74M-24.3%-3.0%53.4%

Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0006.34M43.77M
Cost of Revenue1.5M0001.54M
Gross Profit(1.5M)006.34M42.23M
Gross Margin———100.0%96.5%
Research & Development51.19M59.2M52.14M41.21M56.04M
Selling, General & Admin22.36M29.95M27M24.78M29.71M
Operating Expenses73.55M89.15M79.13M66.93M84.21M
Depreciation & Amortization1.5M1.85M1.9M1.64M1.54M
EBITDA(73.7M)(86.38M)(74.5M)(58M)(33.5M)
EBITDA Margin———-914.3%-76.5%
Operating Income(75.04M)(89.15M)(79.13M)(60.58M)(41.98M)
Operating Margin———-954.9%-95.9%
Interest Income6000003.4M
Interest Expense600K00100K0
Other Income / Expenses(756K)927K2.73M2.34M6.95M
Income Before Tax(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Pre-Tax Margin———-918.0%-80.1%
Income Tax Expense00000
Net Income(75.8M)(88.22M)(76.4M)(58.24M)(35.04M)
Net Margin———-918.0%-80.1%
EPS (Basic)(189.28)(45.08)(38.92)(15.26)(4.19)
EPS (Diluted)(189.28)(45.08)(38.92)(15.26)(4.19)
Weighted Avg Shares400.45K1.96M1.96M3.82M83.59M
Weighted Avg Shares (Diluted)400.45K1.96M1.96M3.82M83.59M

Xilio Therapeutics, Inc.

NASDAQ:XLO

Intrinsic Alpha fair value

Locked

Current Price

$7.63

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.